Table 2 ∣.
Summary of response data for patients who experienced intracranial benefit (RANO and RECIST)
| Case no. | Cohort | Primary tumor histology |
Breast cancer subtype | Best overall response (RANO) |
Best extracranial response (RECIST) |
Reason off treatment |
|---|---|---|---|---|---|---|
| 7 | B | Breast | HR + HER2+ | SD | PD | PD |
| 8 | B | Melanoma | CR | PR | Toxicity | |
| 9 | B | Breast | Triple-negative | SD | Unevaluable | PD |
| 16 | B | Pituitary | SD | Unevaluable | Withdrew consent | |
| 25 | B | Breast | HR + HER2+ | SD | PD | PD |
| 34 | B | NSCLC | SD | SD | PD | |
| 40 | B | Breast | HR + HER2+ | SD | SD | Toxicity |
| 47 | B | Pituitary | SD | SD | PD | |
| 50 | A | Breast | Triple-negative | SD | PD | PD |
| 51 | B | Breast | HR + HER2− | SD | SD | PD |
| 56 | A | NSCLC | PR—unsustained | PD | PD | |
| 57 | B | NSCLC | CR | SD | Toxicity | |
| 58 | B | Breast | Triple-negative | SD | PD | PD |
| 62 | B | Advanced sinonasal ACC | SD | Unknown | PD | |
| 63 | B | Alveolar soft-part sarcoma | PR—sustained | SD | On treatment | |
| 66 | B | Breast | HR + HER2− | SD | SD | PD |
| 67 | B | Breast | HR + HER2 unknown | SD | SD | Withdrew consent |
| 68 | B | Breast | HR− HER2+ | SD | SD | PD |
| 69 | A | Ovarian | SD | PD | PD | |
| 70 | B | Breast | Triple-negative | SD | PR | PD |
| 71 | B | Melanoma | SD | PD | PD | |
| 74 | B | Breast | HR + HER2+ | SD | SD | PD |
| 77 | B | Breast | HR + HER2− | SD | PD | PD |
| 78 | B | Prostate | PR—unsustained | SD | PD |